Financial Architects, Inc Cel Sci Corp Transaction History

Financial Architects, Inc

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2020 Nov 09, 2020	SELL	$11.69 - $14.54 $116 - $145	-10 Closed	0 $0
Q4 2019 Feb 14, 2020	SELL	$6.71 - $9.55 $9,394 - $13,370	-1,400 Reduced 99.29%	10 $0
Q3 2019 Nov 06, 2019	BUY	$6.0 - $9.6 $8,400 - $13,440	1,400 Added 14000.0%	1,410 $13,000
Q1 2019 May 13, 2019	BUY	$2.58 - $3.54 $25 - $35	10 New	10 $0
Q1 2019 May 03, 2019	SELL	$2.58 - $3.54 $25 - $35	-10 Closed	0 $0
Q3 2017 Nov 01, 2017	BUY	$1.59 - $3.0 $15 - $30	10	10 $0

27.1K

150K

Ticker CVM
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,367,500
Market Cap $26.9M
Description
CEL-SCI Corporation engages in the research and development of immunotherapy for the treatment of cancer and infectious diseases. The company's lead investigational immunotherapy is Multikine, which is under phase III clinical trial for the treatment of head and neck cancer. Its Ligand Epitope Antigen Presentation System (LEAPS), a pre-clinical ...

Get notified when there are updates to the investment portfolio of Financial Architects, Inc, based on Form 13F filings with the SEC.

Stay updated on Financial Architects, Inc with notifications on news.